Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases

A cardiovascular and cerebrovascular disease, ginsenoside technology, applied in the field of medicine, can solve the problems of increasing the risk of adverse reactions of patients, uncontrolled mass ratio, and increased incidence of adverse reactions, so as to achieve hemolysis and coagulation safety and improve safety and effectiveness, the effect of component fixation

Active Publication Date: 2013-11-20
DALI PHARMA
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] However, the chemical composition of Shenmai Injection is very complex, and currently only ginsenoside Rb is known and used as a quality control indicator 1 , Ginsenoside Rg 1 , ginsenoside Re, and ginsenoside Rb 2 , Ginsenoside Rc, Ophiopogon japonicus saponin D and other ingredients are not low in Shenmai injection, but the mass ratio is not controlled, and due to individual differences in red ginseng and Ophiopogon japonicus medicinal materials and the different preparation processes of each manufacturer Ginsenoside Rb in different batches of Shenmai Injection 1 , Ginsenoside Rg 1 , Ginsenoside Rb 2 , Ginsenoside Rc, Ginsenoside Re, Ophiopogonoside D content all have varying degrees of difference and different proportions, precisely because ginsenoside Rb 1 , Ginsenoside Rg 1 , Ginsenoside Rb 2 , ginsenoside Rc, ginsenoside Re, ophiopogonin D content, the stability of the drug effect is not high, which increases the risk of adverse reactions in patients during clinical use, and the incidence of adverse reactions is increasing year by year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases
  • Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases
  • Ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1 prepares the injection of composition of the present invention

[0040] The sample prepared by the above-mentioned steps is detected by the above-mentioned method again, and the purity is respectively ginsenoside Rb 1 99.6%, Ginsenoside Rg 1 99.5%, Ginsenoside Rb 2 99.0%, ginsenoside Rc99.2%, ginsenoside Re99.3%, ophiopogon saponin D99.4%.

[0041] Ginsenoside Rb 1 32%, Ginsenoside Rg 1 18%, Ginsenoside Rb 2 14%, ginsenoside Rc14%, ginsenoside Re8%, ophiopogon saponin D14%, add appropriate amount of water for injection to dissolve, ultrafiltration, potting, and make injection.

Embodiment 2

[0042] Embodiment 2 prepares the injection of composition of the present invention

[0043] The sample prepared by the above-mentioned steps is detected by the above-mentioned method again, and the purity is respectively ginsenoside Rb 1 91.3%, Ginsenoside Rg 1 92.1%, ginsenoside Rb 2 90.0%, ginsenoside Rc91.5%, ginsenoside Re90.8%, ophiopogon saponin D91.4%.

[0044] Ginsenoside Rb 1 28%, Ginsenoside Rg 1 20%, Ginsenoside Rb 2 14%, ginsenoside Rc14%, ginsenoside Re10%, ophiopogon saponin D14%, add appropriate amount of water for injection to dissolve, then add appropriate amount of activated carbon, filter, pot, and make injection.

Embodiment 3

[0045] Embodiment 3 prepares the lyophilized powder injection of composition of the present invention

[0046] The sample prepared by the above-mentioned steps is detected by the above-mentioned method again, and the purity is respectively ginsenoside Rb 1 85.6%, Ginsenoside Rg 1 86.2%, ginsenoside Rb 2 85.1%, ginsenoside Rc85.8%, ginsenoside Re85.3%, ophiopogon saponin D86.0%.

[0047] Ginsenoside Rb 1 28%, Ginsenoside Rg 1 22%, Ginsenoside Rb 2 14%, ginsenoside Rc14%, ginsenoside Re8%, ophiopogon saponin D14%, add appropriate amount of water for injection to dissolve, filter, potting, and make freeze-dried powder for injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A ginsenoside-ophiopogonin D composition for treating cardiovascular and cerebrovascular diseases comprises the components by weight percent: 28-32% of ginsenoside Rb1, 18-22% of ginsenoside Rg1, 14-16% of ginsenoside Rb2, 14-16% of ginsenoside Rc, 8-12% of ginsenoside Re, and 14-16% of ophiopogonin D. The advantages are that: the provided ginsenoside-ophiopogonin D composition has fixed and scientific components, controllable and stable quality, substantial drug effect and higher security, same or slightly better drug effects on (myocardial, cerebral and lung) ischemia-reperfusion injury resistance, thrombosis resistance, arteriosclerosis resistance, arrhythmia resistance and the like than shenmai injection, and more safety on acute toxicity, abnormal toxicity, hemolysis, coacervation and the like than shenmai injection. The ginsenoside-ophiopogonin D composition has the advantages of clear and fixed components, more stable and controllable quality, substantial treatment effect and higher security.

Description

technical field [0001] The present invention relates to the technical field of medicine, in particular to a composition of ginsenoside and ophiopogon saponin D for treating cardiovascular and cerebrovascular diseases, specifically composed of ginsenoside Rb 1 , Ginsenoside Rg 1 , Ginsenoside Rb 2 , Ginsenoside Rc, Ginsenoside Re, Ophioside D. Background technique [0002] Cardiovascular and cerebrovascular diseases are the primary diseases that threaten human health. According to the World Health Organization (WHO) statistics on the death of various diseases in the world in 1996, there are at least 450 million people with cardiovascular and cerebrovascular diseases worldwide, which is the disease that causes the most death and disability. Coronary heart disease, stroke and other heart diseases The total number of deaths is 14 million, accounting for 28.8% of the total number of deaths, and it is showing an upward trend year by year. According to incomplete statistics, in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/10A61P9/06A61P7/02A61P9/00
Inventor 黄照昌李红艳段秀芬张静寸桂菊
Owner DALI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap